Abstract
Purpose Molecular markers, such as FOXO1 fusion genes and TP53 and MYOD1 mutations, increasingly influence risk-stratified treatment selection for pediatric rhabdomyosarcoma (RMS). This study aims to integrate molecular and clinical data to produce individualized prognosis predictions that can further improve treatment selection.
Patients and Methods Clinical variables and somatic mutation data for 20 genes from 641 RMS patients in the United Kingdom and the United States were used to develop three Cox proportional hazard models for predicting event-free survival (EFS). The ‘Baseline Clinical’ (BC) model included treatment location, age, fusion status, and risk group. The ‘Gene Enhanced 2’ (GE2) model added TP53 and MYOD1 mutations to the BC predictors. The ‘Gene Enhanced 6’ (GE6) model further included NF1, MET, CDKN2A, and MYCN mutations, selected through LASSO regression. Model performance was assessed using likelihood ratio (LR) tests and optimism-adjusted, bootstrapped validation and calibration metrics.
Results The GE6 model demonstrated superior predictive performance, offering 39% more predictive information than the BC model (LR p<0.001) and 15% more than the GE2 model (LR p<0.001). The GE6 model achieved the highest discrimination with a C-index of 0.7087, a Nagalkerke R2 of 0.205, and appropriate calibration. Mutations in TP53, MYOD1, CDKN2A, MET, and MYCN were associated with higher hazards, while NF1 mutation correlated with lower hazard. Individual prognosis predictions varied between models in ways that may suggest different treatments for the same patient. For example, the 5-year EFS for a 10-year-old patient with high-risk, fusion-negative, NF1-positive disease was 50.0% (95% confidence interval: 39-64%) from BC but 76% (64-90%) from GE6.
Conclusion Incorporating molecular markers into RMS prognosis models improves prognosis predictions. Individualized prognosis predictions may suggest alternative treatment regimens compared to traditional risk-classification schemas. Improved clinical variables and external validation are required prior to implementing these models into clinical practice.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Institutes of Health research grant K12CA090433.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The source data are available on the National Cancer Institute's Center for Cancer Research Oncogenomics data platform at https://clinomics.ccr.cancer.gov/clinomics/public.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Research Support: National Institutes of Health (K12CA090433)
Presentation: Abstract accepted for oral presentation at the International Society of Pediatric Oncology Annual Congress in October 2024
Context Summary
Key objective: Can incorporating additional molecular biomarkers beyond PAX::FOXO1 fusion status, and TP53 and MYOD1 mutations improve individualized prognosis predictions for pediatric rhabdomyosarcoma patients? This study evaluates novel gene mutations to enhance risk stratification beyond current clinical practices.
Knowledge generated: Mutations in CDKN2A, MET, and MYCN were associated with worse prognosis, while NF1 mutations correlated with improved outcomes. Individual patient survival predictions changed when these new molecular markers were included in prediction models in ways that suggest different risk categories and treatment assignments compared to current classification methods.
Data Availability
The source data are available on the National Cancer Institute's Center for Cancer Research Oncogenomics data platform at https://clinomics.ccr.cancer.gov/clinomics/public.
